Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Yuan Cheng,Jiali Liu,Xiang Tan,Yi Dai,Chune Xie,Xiaohong Li,Qiongqiong Lu,Fushun Kou,Hui Jiang,Junxiang Li

DOI: https://doi.org/10.1007/s10620-020-06141-5

2020-02-24

Digestive Diseases and Sciences

Abstract:Gastroesophageal reflux disease (GERD) is a common disorder, and is typically treated with proton-pump inhibitors (PPIs) as the recommended first-line therapy. Recently, a new potassium-competitive acid blocker, vonoprazan, was launched in Japan. It is uncertain whether the standard dose of vonoprazan 20 mg is superior to that of PPIs for GERD, so a direct comparison of the therapeutic effects and adverse events between vonoprazan 20 mg and PPIs is needed.

gastroenterology & hepatology